We are live on ! Find out more
DOVA

Dova Pharmaceuticals, Inc. Common Stock
DOVA

Delisted

DOVA was delisted on the 11th of November, 2019.

Back to rankings

39 hedge funds and large institutions have $160M invested in Dova Pharmaceuticals, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 4

75% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 12

30% more funds holding

Funds holding: 30 → 39 (+9)

19% more capital invested

Capital invested by funds: $135M → $160M (+$25.3M)

Holders
39
Holders Change
+9
Holders Change %
+30%
% of All Funds
0.97%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
21
Increased
10
Reduced
4
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NC
Nexthera Capital
New York
+$5.69M
2
BlackRock
BlackRock
New York
+$5.42M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$3.54M
4
Wells Fargo
Wells Fargo
California
+$2.95M
5
PC
Pier Capital
Connecticut
+$1.5M

Top Sellers

Rank Fund Capital Flow
1
MIM
Monashee Investment Management
Massachusetts
-$2.23M
2
PC
Paulson & Co
New York
-$1.68M
3
PWAM
Park West Asset Management
California
-$1.34M
4
Millennium Management
Millennium Management
New York
-$1.05M
5
OA
Omega Advisors
New York
-$892K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$48.7M +$745K +31,422 +2%
PA
2
Perceptive Advisors
New York
$42.6M +$1.13M +47,516 +3%
FI
3
Fosun International
China
$17.2M +$1.42M +60,000 +9%
NC
4
Nexthera Capital
New York
$10.6M +$5.69M +240,060 +121%
PC
5
Paulson & Co
New York
$9.98M -$1.68M -70,951 -11%
Wells Fargo
6
Wells Fargo
California
$7.87M +$2.95M +124,287 +62%
BlackRock
7
BlackRock
New York
$5.55M +$5.42M +228,509 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$4.05M +$3.54M +149,153 +852%
PC
9
Pier Capital
Connecticut
$2.83M +$1.5M +63,289 +118%
SFM
10
Sphera Funds Management
Israel
$1.9M -$396K -16,716 -18%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$1.28M +$1.25M +52,793 New
Northern Trust
12
Northern Trust
Illinois
$1.28M +$1.25M +52,685 New
CI
13
Conning Inc
Connecticut
$1.21M – – –
Ameriprise
14
Ameriprise
Minnesota
$1.2M +$458K +19,300 +64%
State Street
15
State Street
Massachusetts
$833K +$812K +34,262 New
Norges Bank
16
Norges Bank
Norway
$425K – – –
Bank of New York Mellon
17
Bank of New York Mellon
New York
$340K +$332K +13,998 New
Barclays
18
Barclays
United Kingdom
$324K +$317K +13,363 New
Millennium Management
19
Millennium Management
New York
$247K -$1.05M -44,183 -81%
LCM
20
Laurion Capital Management
New York
$243K – – –
Charles Schwab
21
Charles Schwab
California
$241K +$235K +9,900 New
TA
22
Teachers Advisors
New York
$222K +$217K +9,152 New
Morgan Stanley
23
Morgan Stanley
New York
$209K +$204K +8,598 New
TCIM
24
TIAA CREF Investment Management
New York
$204K +$199K +8,410 New
California State Teachers Retirement System (CalSTRS)
25
California State Teachers Retirement System (CalSTRS)
California
$202K +$197K +8,300 New
1
2 3

DOVA Hedge Fund Activity: Q3 2017 in Review

39 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Dova Pharmaceuticals, Inc. Common Stock (DOVA) for Q3 2017, worth a combined $160M — up 19% from $135M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new DOVA positions and 12 closed out — a net gain of 9 holders — while 10 added to existing stakes and 4 trimmed.

The largest buyer was Nexthera Capital, adding an estimated $5.69M. The largest seller was Monashee Investment Management, exiting entirely with an estimated $2.23M sold.

  • 39 institutional investors held Dova Pharmaceuticals, Inc. Common Stock (DOVA) as of Q3 2017, up from 30 in Q2 2017.
  • Funds reported $160M of Dova Pharmaceuticals, Inc. Common Stock stock for Q3 2017, up 19% quarter-over-quarter.
  • 21 funds opened new Dova Pharmaceuticals, Inc. Common Stock positions in Q3 2017 and 12 closed out, a net change of +9 holders.
  • The largest Dova Pharmaceuticals, Inc. Common Stock buyer in Q3 2017 was Nexthera Capital, an estimated $5.69M added.
  • The largest Dova Pharmaceuticals, Inc. Common Stock seller in Q3 2017 was Monashee Investment Management, an estimated $2.23M sold.

Based on aggregated 13F filings for Q3 2017.